Menu
Back to Journals » International Journal of Nanomedicine » Volume 8 » Issue 1
Intravenous magnetic nanoparticle cancer hyperthermia
Authors Huang HS, Hainfeld JF
Received 7 February 2013
Accepted for publication 22 March 2013
Published 17 July 2013 Volume 2013:8(1) Pages 2521—2532
DOI https://doi.org/10.2147/IJN.S43770
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Video abstract presented by HS Huang and JF Hainfeld.
Views: 6134
Hui S Huang, James F Hainfeld
Nanoprobes, Yaphank, NY, USA
Abstract: Magnetic nanoparticles heated by an alternating magnetic field could be used to treat cancers, either alone or in combination with radiotherapy or chemotherapy. However, direct intratumoral injections suffer from tumor incongruence and invasiveness, typically leaving undertreated regions, which lead to cancer regrowth. Intravenous injection more faithfully loads tumors, but, so far, it has been difficult achieving the necessary concentration in tumors before systemic toxicity occurs. Here, we describe use of a magnetic nanoparticle that, with a well-tolerated intravenous dose, achieved a tumor concentration of 1.9 mg Fe/g tumor in a subcutaneous squamous cell carcinoma mouse model, with a tumor to non-tumor ratio > 16. With an applied field of 38 kA/m at 980 kHz, tumors could be heated to 60°C in 2 minutes, durably ablating them with millimeter (mm) precision, leaving surrounding tissue intact.
Keywords: magnetic nanoparticles, hyperthermia, cancer, alternating magnetic field, intravenous delivery
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.